valacyclovir and plerixafor

This review article, while autobiographical to some extent, describes the discovery of ten (classes of) antiviral compounds that have made (or just did not make) it to the market for the therapy of viral infections, but each in its own way influenced the landscape of our dealing with virus infections: (i) valaciclovir, (ii) BVDU, (iii) DHPA, (iv) cidofovir, (v) adefovir, (vi) tenofovir, (vii) stavudine, (viii) HEPT, (ix) TIBO, and (x) AMD3100. Successful drug development, as is certainly true for antiviral drugs and exemplified for the acyclic nucleoside phosphonates cidofovir, adefovir and tenofovir, requires patience and perseverance, and a close continuous and dedicated interaction between Chemistry, Biology/Medicine and Industry.

Topics: Acyclovir; Adenine; Antiviral Agents; Benzodiazepines; Benzylamines; Cidofovir; Cyclams; Cytosine; Heterocyclic Compounds; Humans; Imidazoles; Nucleosides; Organophosphonates; Tenofovir; Valacyclovir; Valine; Virus Diseases